Avacincaptad Pegol
Ongoing Research and Future Outlook
Comorbidities
Current Approved Pharmacological Therapies
VIDEO: ‘Still in the dark ages’ in how to best monitor geographic atrophy
CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.
Avacincaptad pegol may help preserve driving eligibility in patients with GA
Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.
Reduction in GA lesion growth may be greater with pegcetacoplan than avacincaptad pegol
Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.
VIDEO: Macular neovascularization did not impact reduction in GA growth in GATHER trials
In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.
VIDEO: Study focuses on GA lesion growth with monthly pegcetacoplan, avacincaptad pegol
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.
VIDEO: Geographic atrophy enters new era with two treatments
Durga S. Borkar, MD, MMCi, assistant professor of ophthalmology and director of clinical data science at Duke University Eye Center, discusses recent FDA approvals that have been useful in the treatment of geographic atrophy.
VIDEO: Analysis compares phase 3 data of geographic atrophy treatments
In this Healio Video Perspective from the Macula Society meeting, Dilsher Dhoot, MD, discusses data from three phase 3 trials involving pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.